key: cord-0997271-hse8atu4
authors: Collins, Sylva H.; Levenson, Mark S.
title: Comment on “Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic”
date: 2020-07-06
journal: Statistics in biopharmaceutical research
DOI: 10.1080/19466315.2020.1779123
sha: 577b2e8de3b7738e3362b3fc5660e55ff065d2ee
doc_id: 997271
cord_uid: hse8atu4

nan

COVID-19 has imposed significant difficulties in the conduct and analysis of clinical trials. The full extent of the consequence of COVID-19 will not be known for some time. Nonetheless, the impact will be great. All parties have an interest in ensuring that the time and effort of trial participants and other resource investments are put to the best possible use. Many products under development may be life-saving or life-altering. In spite of the many disruptions on trial conduct imposed by COVID-19, clinical trials require rigorous design and analysis and the assessment and control of bias and uncertainty. Statisticians have a significant role in assessing and mitigating the impact of these disruptions on the integrity of the results of the trial. Missing data, COVID-19 related intercurrent events, and premature termination of trials all call for careful statistical analysis and interpretation.

The authors of the white paper (Meyer et al. 2020 ) have addressed several aspects of the impact of COVID-19. We appreciate their efforts to bring clarity to these important issues. Missing data, intercurrent events, and premature trial terminations are not new. As the authors point out, wellestablished statistical methods exist to deal with these issues.

The estimand approach from the ICH E9-R1 Addendum (ICH 2019) provides an effective framework to address the current complications. The goal is to establish clear trial objectives and to focus on considerations needed to achieve these objectives. The authors propose that a hypothetical estimand that targets the treatment effect as if the COVID-19 intercurrent events did not happen may be appropriate. We note that this may be an estimand of interest, but the choice must be balanced with practical considerations of what can be reliably and robustly estimated in present circumstances.

The authors generally favor using the originally planned endpoint. However, COVID-19 has severely impaired face-to-face meetings between physician and patient. In some cases, it may be necessary to collect the endpoint through different means. For example, telemedicine and local laboratory data might be substituted for other means of collecting information. We agree with the position that the endpoint should remain the same to the extent possible but recognize that we are facing special circumstances. The specific details of the disruption of clinical trials by COVID-19 are expected to be so diverse that no single solution will be appropriate for all trials. As the authors suggest, discussions with regulators will be helpful. We concur that such discussion is necessary for both the choice of the estimand and the associated estimation.

The authors contend that the current approaches for handling missing data are appropriate for COVID-19 complications. We agree that categorization of the missing data mechanism according to MCAR, MAR, and MNAR is relevant to the current situation. However, particular care should be given to their application. For example, the use of the MCAR assumption when a site has suspended activities needs to be carefully considered. Participants who were still in the trial at the time the site was impacted may differ from the full set of randomized participants.

We are interested in further discussion on trial adaptations, including modifying sample size, stopping a trial earlier than planned, or adding additional interim analyses. We are also interested in the authors' suggestion that studies with meaningful observed treatment effects but that did not meet their statistical objectives because of COVID-19 may still be useful as part of the totality of evidence. The proper use of such trials will require thoughtful discussion across multiple parties including careful consideration of regulatory requirements.

We agree with the authors on the need for a range of sensitivity analyses and supportive analyses. These include analyses evaluating the missing data mechanism, the impact of alternative endpoint measurements, and the impact of COVID-19 intercurrent events.

We wish to thank the authors for their contribution to this important area. The white paper provides statisticians with valuable insight. We recognize that although it is important to address the impact of COVID-19 proactively, we are still learning about the extent of the impact and the methods for addressing the impact. We believe it is important for trial sponsors and regulators to work jointly on the most appropriate approaches to make the best use of ongoing trials affected by COVID-19. We encourage the statistical community to continue to be engaged in this important area.

Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials

Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic